Junshi Biosciences shareholder to reduce stake for fund maturity, liquidity

Shanghai Tanying Investment Partnership, a substantial shareholder in Shanghai Junshi Biosciences Co., Ltd., intends to reduce its stake by a maximum of 20,533,797 shares. This reduction, not exceeding 2% of the company's total share capital, will be executed through block trading between January 13, 2026, and April 10, 2026. Shanghai Tanying currently holds 59,459,326 A shares, representing 5.7914% of the company's total share capital.

The reduction plan is driven by the maturity of the fund and liquidity considerations for Shanghai Tanying, a private equity fund. The price for the reduction will be determined based on market price, with adjustments for any ex-rights or ex-dividend events. This follows a prior reduction by Shanghai Tanying of 12,000,000 shares between September 5, 2025, and September 22, 2025, at prices ranging from RMB43.13 to RMB48.46.

The company's board emphasized that the plan complies with relevant regulations and does not anticipate a material impact on Junshi Biosciences' governance structure or operations. However, uncertainties regarding the exact timing, price, and quantity of the reduction remain, as Shanghai Tanying will make its final decision based on fund operations and market conditions.